What is the definition, pathophysiology, classification, and treatment of atrial fibrillation?

Atrial Fibrillation: Definition, Pathophysiology, Types, and Treatment

Definition

Atrial fibrillation is a supraventricular tachyarrhythmia characterized by uncoordinated electrical activation of the atria resulting in ineffective atrial contraction, reflected on ECG by the absence of discernible regular P waves and irregularly irregular ventricular activation 1. The diagnosis requires documentation of AF lasting at least 30 seconds on any ECG recording 2, 3.

AF is the most common sustained cardiac arrhythmia, accounting for approximately one-third of hospitalizations for rhythm disturbances 2, 3. It affects 1-2% of the general population, with prevalence increasing dramatically with age—from <1% in those under 50 years to 4% at age 65 and 12% in those over 80 years 4, 3.

---

Pathophysiology

The pathophysiology of AF involves multiple interacting mechanisms at the cellular, tissue, and organ levels 5, 6:

Focal Triggers and Ectopic Activity

• Pulmonary veins are the primary source of ectopic triggers in most patients, generating rapid focal discharges (typically >250 beats/min) that initiate AF 2, 3
• Ion channel abnormalities lead to abnormal automaticity and triggered activity
• Calcium handling abnormalities in atrial myocytes promote afterdepolarizations

Reentrant Mechanisms

• Multiple wavelets of reentry circulate simultaneously through the atria
• Shortened atrial refractoriness and slowed conduction velocity create substrate for reentry
• Structural heterogeneity and fibrosis provide anatomic obstacles that anchor reentrant circuits 6

Electrical and Structural Remodeling

• "AF begets AF": Sustained AF causes progressive electrical remodeling within hours to days
• Ion channel downregulation (particularly L-type calcium channels) shortens action potential duration
• Structural remodeling develops over weeks to months, including atrial fibrosis, myocyte hypertrophy, and inflammatory changes
• This creates "atrial cardiomyopathy" that perpetuates the arrhythmia 7

Autonomic Neural Components

• Both sympathetic and parasympathetic activation can trigger and maintain AF
• Autonomic ganglia in atrial fat pads play important modulatory roles 6

---

Classification and Types

Current Classification System (2024 ACC/AHA/HRS)

The 2024 guidelines introduce a stage-based classification that recognizes AF as a disease continuum 8, 9:

Stage 1: At Risk for AF

• Presence of risk factors (hypertension, obesity, diabetes, sleep apnea, etc.)
• No documented AF episodes
• Focus on prevention and risk factor modification

Stage 2: Pre-AF

• Evidence of structural or electrical substrate predisposing to AF
• Atrial cardiomyopathy markers present (left atrial enlargement, atrial fibrosis)
• No documented AF episodes yet

Stage 3: AF

• Documented AF episodes present
• Includes all temporal patterns (see below)
• Includes patients with successful AF ablation

Stage 4: Permanent AF

• Continuous AF where patient and physician have decided not to pursue rhythm control
• Acceptance of AF as the baseline rhythm

Temporal Pattern Classification

The temporal patterns remain clinically relevant within the staging system 1, 2:

First-Diagnosed AF

• Initial detection regardless of duration or symptoms
• May be paroxysmal, persistent, or permanent at presentation 10

Paroxysmal AF

• Self-terminating episodes, typically within 7 days (most <48 hours)
• May terminate spontaneously or with intervention
• History of ≥2 episodes 11

Persistent AF

• Continuous AF lasting >7 days
• Requires cardioversion (electrical or pharmacological) for termination
• Does not self-terminate 1

Long-Standing Persistent AF

• Continuous AF ≥12 months duration
• Rhythm control still being considered as treatment option
• Distinguished from permanent AF by intent to restore sinus rhythm 1

Permanent AF

• Continuous AF where rhythm control is no longer pursued
• Represents shared decision between patient and physician to accept AF 1

Other Important Classifications

Valvular vs. Non-Valvular AF

• Valvular AF: AF with moderate-to-severe mitral stenosis or mechanical prosthetic heart valve 10
• Non-valvular AF: All other AF (includes bioprosthetic valves, mitral regurgitation, other valve disease) 10
• This distinction is critical for anticoagulation decisions

Primary vs. Secondary AF

• Primary AF: Occurs in context of established pathophysiological substrate
• Secondary AF: Occurs with self-limited precipitant (surgery, acute illness, alcohol)
• Secondary AF has variable recurrence risk depending on substrate 10

---

Treatment

Treatment of AF focuses on three pillars: stroke prevention, symptom management through rate or rhythm control, and risk factor modification 8, 9.

1. Anticoagulation for Stroke Prevention

Risk Stratification

• Use CHA₂DS₂-VASc score to estimate annual stroke risk 8:
  • Congestive heart failure (1 point)
  • Hypertension (1 point)
  • Age ≥75 years (2 points)
  • Diabetes (1 point)
  • Stroke/TIA/thromboembolism history (2 points)
  • Vascular disease (1 point)
  • Age 65-74 years (1 point)
  • Sex category (female, 1 point)

Anticoagulation Recommendations 8:

• Score ≥2 in men or ≥3 in women: Oral anticoagulation recommended (Class I)
• Score 1 in men or 2 in women: Consider anticoagulation based on individual risk factors and patient preference
• Direct oral anticoagulants (DOACs) preferred over warfarin in non-valvular AF (Class I)
  • Apixaban, rivaroxaban, edoxaban, or dabigatran
  • Superior or non-inferior efficacy with lower bleeding risk than warfarin
• Warfarin required for mechanical valves or moderate-to-severe mitral stenosis
• Aspirin is NOT recommended for stroke prevention in AF—ineffective and still carries bleeding risk 10

Left Atrial Appendage Occlusion

• Class IIa recommendation for patients with long-term contraindications to anticoagulation 8, 9
• Upgraded from previous guidelines based on improved safety and efficacy data

2. Rate Control

Target Heart Rate

• Lenient rate control (resting HR <110 bpm) is non-inferior to strict control (<80 bpm) and better tolerated 10
• Stricter control may be needed if symptoms persist or tachycardia-induced cardiomyopathy develops

Pharmacological Rate Control 11:

• Beta-blockers (metoprolol, carvedilol, bisoprolol): First-line for most patients
• Non-dihydropyridine calcium channel blockers (diltiazem, verapamil): Alternative or combination therapy
• Digoxin: Useful in heart failure or sedentary patients; less effective during exercise
• Avoid in accessory pathway-mediated AF (can accelerate ventricular response)

Non-Pharmacological Rate Control

• AV node ablation with permanent pacemaker: For refractory rate control 11
• Consider biventricular pacing in patients with heart failure

3. Rhythm Control

Early Rhythm Control Strategy

• Strongly recommended for patients with recent-onset AF (<1 year) to prevent progression and improve outcomes 8, 9
• Reduces cardiovascular events, hospitalizations, and mortality compared to delayed rhythm control

Pharmacological Rhythm Control 11:

For patients WITHOUT structural heart disease:

• Flecainide or propafenone (Class IC agents)
• Sotalol (Class III agent)

For patients WITH structural heart disease or heart failure:

• Amiodarone: Most effective but significant toxicity profile (thyroid, pulmonary, hepatic)
• Dofetilide: Requires in-hospital initiation with QT monitoring

Avoid Class IC agents in:

• Coronary artery disease
• Left ventricular dysfunction
• Structural heart disease

Cardioversion 11:

• Electrical cardioversion: More effective than pharmacological (80-90% success)
  • Biphasic waveforms preferred over monophasic
  • Anticoagulation required if AF >48 hours or unknown duration
• Pharmacological cardioversion:
  • IV ibutilide (success within 1 hour)
  • Oral or IV amiodarone (success over days)

Catheter Ablation

The 2024 guidelines significantly expanded ablation indications 8, 9:

• Class I (strongly recommended) as FIRST-LINE therapy in selected patients with symptomatic paroxysmal AF

  • Generally younger patients with few comorbidities
  • Superior to antiarrhythmic drugs for maintaining sinus rhythm and preventing AF progression

• Class I for heart failure with reduced ejection fraction

  • Superior to medical therapy for reducing mortality and hospitalizations
  • Should be considered early in patients with persistent AF and HFrEF

• Pulmonary vein isolation (PVI) is the cornerstone procedure 11

  • Radiofrequency or cryoablation energy sources
  • Success rates: 60-80% for paroxysmal AF, 40-60% for persistent AF

• Additional ablation strategies for persistent AF:

  • Linear lesions (roof line, mitral isthmus)
  • Complex fractionated electrogram ablation
  • Posterior wall isolation

Surgical Ablation 11, 1:

• Concomitant AF ablation (Class IIa) should be considered during cardiac surgery
• Stand-alone surgical ablation (Class IIb): May be considered for symptomatic AF refractory to drugs and failed catheter ablation
• Maze procedure (Cox-Maze) or thoracoscopic approaches

4. Risk Factor Modification and Upstream Therapy

Critical for preventing AF onset and progression 8:

• Weight loss: 10% weight reduction significantly reduces AF burden in obese patients
• Alcohol moderation: Limit to ≤1 drink/day; complete abstinence if alcohol-induced AF
• Blood pressure control: Target <130/80 mmHg
• Obstructive sleep apnea treatment: CPAP therapy reduces AF recurrence
• Exercise: Regular moderate-intensity exercise (avoid extreme endurance training)
• Smoking cessation: Mandatory
• Diabetes management: Optimize glycemic control

Upstream Therapy 6:

• ACE inhibitors or ARBs: May reduce AF incidence in hypertension and heart failure
• Statins: Potential benefit in post-cardiac surgery AF prevention
• Anti-inflammatory approaches under investigation

5. Management of Specific Scenarios

Device-Detected AF 8:

• Episodes >24 hours: Consider anticoagulation based on stroke risk
• Episodes 5-24 hours: Individualize based on stroke risk and episode frequency
• Shorter episodes: Monitor and reassess

Post-Operative AF 1, 12:

• Prevention: Perioperative amiodarone or beta-blockers (Class IIa)
• Posterior pericardiotomy during surgery reduces incidence (Class IIa)
• Treatment: Rate control, consider cardioversion if hemodynamically unstable
• Anticoagulation decisions based on recurrence risk and stroke risk factors

AF with Acute Coronary Syndrome/PCI:

• Triple therapy (DOAC + aspirin + P2Y12 inhibitor) for 1-7 days post-PCI
• Dual therapy (DOAC + P2Y12 inhibitor) for up to 12 months
• DOAC monotherapy thereafter if no other indication for antiplatelet therapy

---

Treatment Algorithm by Clinical Presentation

Newly Diagnosed AF:

1. Assess hemodynamic stability → Unstable: immediate cardioversion
2. Determine stroke risk (CHA₂DS₂-VASc) → Initiate anticoagulation if indicated
3. Classify temporal pattern and stage
4. Address modifiable risk factors aggressively
5. Choose rate vs. rhythm control based on symptoms, age, comorbidities

Symptomatic Paroxysmal AF:

1. Anticoagulation based on stroke risk
2. Consider catheter ablation as first-line in selected patients (Class I)
3. If ablation declined: antiarrhythmic drugs (flecainide/propafenone if no structural disease; amiodarone if structural disease present)
4. Aggressive risk factor modification

Persistent AF:

1. Anticoagulation based on stroke risk
2. Early rhythm control strategy preferred
3. Cardioversion (electrical preferred)
4. Antiarrhythmic drugs to maintain sinus rhythm
5. Consider catheter ablation if drugs fail or as first-line in appropriate candidates

AF with Heart Failure (HFrEF):

1. Anticoagulation
2. Catheter ablation strongly recommended (Class I) to reduce mortality and hospitalizations
3. If ablation not feasible: amiodarone for rhythm control
4. Optimize heart failure medical therapy

Permanent AF:

1. Anticoagulation based on stroke risk
2. Rate control (lenient target <110 bpm)
3. Treat underlying conditions
4. Risk factor modification to prevent complications

---

Common Pitfalls

• Do not use aspirin for stroke prevention—it doesn't work and still causes bleeding 10
• Do not delay anticoagulation while pursuing rhythm control—stroke risk persists even after cardioversion
• Do not use Class IC antiarrhythmics (flecainide, propafenone) in patients with structural heart disease or coronary disease—risk of proarrhythmia
• Do not forget anticoagulation for at least 4 weeks post-cardioversion regardless of apparent sinus rhythm maintenance
• Do not overlook modifiable risk factors—they are as important as pharmacotherapy for long-term outcomes 8
• Do not assume device-detected AF is benign—episodes >24 hours warrant anticoagulation consideration 8